ClinicalTrialsFinder

Refractory Glioblastoma Clinical Trials in Hangzhou, Zhejiang

1 recruitingHangzhou, Zhejiang, China

Showing 1–1 of 1 trials

Recruiting
Phase 1

B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma

Recurrent GlioblastomaRefractory Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University14 enrolled1 locationNCT07193628